Rodman & Renshaw Boosts Protalix Biotherapeutics Inc (PLX) Price Target to $5.00
Protalix Biotherapeutics Inc (AMEX:PLX) had its price target hoisted by Rodman & Renshaw from $4.00 to $5.00 in a research report report published on Monday. They currently have a buy rating on the stock.
Protalix Biotherapeutics (AMEX:PLX) opened at 1.00 on Monday. The firm has a 50-day moving average of $1.18 and a 200 day moving average of $0.72. The firm’s market capitalization is $124.13 million. Protalix Biotherapeutics has a 12-month low of $0.26 and a 12-month high of $1.51.
Receive News & Ratings for Protalix Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.